Medical deferoxamine mesylate market seen reaching $1.91B by 2030

The medical deferoxamine mesylate market is projected to grow from $1.28 billion in 2025 to $1.38 billion in 2026, with demand tied to iron overload disorders and chronic transfusion care. The Business Research Company says North America led in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Medical deferoxamine mesylate is used to treat iron overload, a complication tied to repeated transfusions and chronic blood disorders. - Growth in transfusion-dependent anemia, thalassemia and sickle cell disease is expanding the patient pool that needs iron chelation therapy. - The market’s forecast points to rising demand for hospital-based treatment and injectable deferoxamine as iron toxicity management becomes more routine.

What happened: - The Business Research Company released its Medical Deferoxamine Mesylate Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report projects the medical deferoxamine mesylate market will rise from $1.28 billion in 2025 to $1.38 billion in 2026. - The report puts the market at $1.91 billion by 2030. - The report says the market is growing at an 8.4% CAGR from 2025 to 2026 and an 8.3% CAGR through 2030. - The report includes a free sample and a full report available here and here.

The details: - Medical deferoxamine mesylate removes excess iron from the body and helps prevent organ damage caused by iron toxicity. - The drug binds surplus iron and supports its removal through urine or bile. - Rising iron overload disorders are the main driver of demand. - These disorders can stem from genetic conditions, frequent transfusions or chronic illnesses. - Better diagnosis of iron overload disorders has also supported market growth. - Wider access to chelation therapies and improved hospital treatment practices have added to demand. - The report cites long-term transfusion therapy for chronic hemoglobinopathies as a factor enlarging the at-risk population. - Better survival rates among patients with chronic blood disorders are increasing the number of people living long enough to develop iron overload complications. - A March 2023 report in the Electronic Journal of General Medicine found 10.73% of patients studied had alpha-thalassemia, 2.24% had beta-thalassemia and 0.29% carried both mutations. - The report says North America led the market in 2025. - The report expects Asia-Pacific to post the fastest growth over the forecast period. - The regional scope also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast suggests iron chelation is moving from a niche treatment area toward a more established part of chronic disease management. - Development of alternative chelation drugs could limit growth, but patient-friendly formulations and rare disease programs may offset that pressure. - The market outlook also reflects a broader shift toward specialty pharmaceuticals and longer-term management of transfusion-related complications.

What's next: - Demand will likely track the pace of rare disease treatment programs, specialty drug investment and adoption of newer iron chelation options. - The Business Research Company expects stronger focus on adherence, injectable deferoxamine use and hospital-based iron overload care. - Market growth will likely be strongest in Asia-Pacific if diagnosis and treatment access continue to improve.

The bottom line: - Medical deferoxamine mesylate is benefiting from more diagnosed iron overload disease, more chronic transfusion care and a growing need for effective chelation therapy.